BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Botox (onabotulinumtoxinA) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Botox (onabotulinumtoxinA)\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07387315-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07387315)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: A Randomized\, Pl
 acebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Inj
 ections\nEstimated primary completion: November 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07387315
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923448-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Botox (onabotulinumtoxinA): Phase 2 readout est. (NCT07923448)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2.\nStudy: Can Trenibotulinu
 mtoxinE Reverse OnabotulinumtoxinA Effect in Treating Lateral Canthal Line
 s?\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07923448
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666347-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07666347)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: Intraarticular I
 njection of Botox and Hyaluronic Acid in Knee Osteoarthritis\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07666347
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867379-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07867379)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: Botulinum Toxin T
 ype A Versus Triamcinolone for Facial Myalgia\nEstimated primary completio
 n: 24 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 onabotulinumtoxina#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07867379
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571889-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07571889)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na\, Migraine.\nStudy: Topic
 al Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin In
 jections for Chronic Migraine\nEstimated primary completion: January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07571
 889
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756580-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT07756580)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: A Study to Evalua
 te Sequential Administration of Injections of AGN-151586 Followed by BOTOX
  in Adult Participants for Treatment of Glabellar Lines\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07756580
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07880860-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Botox (onabotulinumtoxinA): Phase 2 readout est. (NCT07880860)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2.\nStudy: Cleft Lip Scarrin
 g After Botox\nEstimated primary completion: February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07880860
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216886-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT06216886)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: Onabotulinumtoxin
 A for Trigeminal Neuralgia\nEstimated primary completion: 1 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06216
 886
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707791-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07707791)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: Pretibial TENS f
 or Pain and Anxiety During Intravesical OnabotulinumtoxinA Injection\nEsti
 mated primary completion: 20 February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07707791
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04731961-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT04731961)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: Reduction in Num
 ber of Botox Injections for Urgency Urinary Incontinence\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04731961
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903975-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT06903975)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: BoTox Into the St
 ernocleidomastoid Muscles (SCM)\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06903
 975
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796985-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT06796985)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: Botox for Chronic
  Pelvic Pain\nEstimated primary completion: 22 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06796985
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902805-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT06902805)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Efficacy of Two
  Ultrasound-guided Intra-articular Injections of Botox® Combined With Cus
 tom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.\nEstimat
 ed primary completion: May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06902805
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549113-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07549113)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: Comparative Eval
 uation of Preoperative Preparation Methods in Patients With Large Incision
 al Hernias\nEstimated primary completion: 1 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07549113
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794891-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07794891)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: Study to Assess P
 articipant Satisfaction After Jawline and Neck Treatment\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07794891
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646886-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07646886)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: Botulinum Toxin T
 ype A Injection Sites for Oral Commissure Ptosis\nEstimated primary comple
 tion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/on
 abotulinumtoxina#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07646886
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04695600-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT04695600)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Onabotulinum To
 xin A (Botox) in the Treatment of Pharyngo-esophageal Dysphagia\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04695600
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837570-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07837570)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4\, Migraine.\nStudy: Compar
 ison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Ne
 rve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chron
 ic Migraine\nEstimated primary completion: October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07837570
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02019004-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT02019004)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: A Pilot Study Tes
 ting Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Faci
 al Wrinkles\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02019004
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220382-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Botox (onabotulinumtoxinA): Phase 4 readout est. (NCT07220382)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 4.\nStudy: Preoperative BOTO
 X® Injection for Large Ventral Hernia Repair\nEstimated primary completio
 n: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 onabotulinumtoxina#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07220382
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721520-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT06721520)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Effectiveness o
 f Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06721520
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05698979-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Botox (onabotulinumtoxinA): Phase 3 readout est. (NCT05698979)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 3.\nStudy: Evaluation of Bot
 ulinum TOXin Type A in the Treatment of Buerger's Disease\nEstimated prima
 ry completion: February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05698979
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648290-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT07648290)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: Self-Start Triage
  Model for Post-Botox® Lower Urinary Tract Symptoms\nEstimated primary co
 mpletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07648290
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793683-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT06793683)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: Early BOTOX After
  Spinal Cord Injury\nEstimated primary completion: 30 April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06793683
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577310-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07577310)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: False Vocal Fold
  vs EMG Guided Botox for Vocal Tremor\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtox
 ina#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07577310
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796490-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Botox (onabotulinumtoxinA): Phase 1/2 readout est. (NCT07796490)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1/2.\nStudy: Neoadjuvant Int
 raprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk 
 Localized Prostate Cancer\nEstimated primary completion: 1 November 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077964
 90
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040813-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Botox (onabotulinumtoxinA): Phase 3 readout est. (NCT07040813)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 3\, Migraine.\nStudy: The No
 rdic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumto
 xin A Dual Therapy Compared to CGRP mAbs Monotherapy\nEstimated primary co
 mpletion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07040813
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930143-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07930143)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: EndoFLIP-Guided 
 Initial Management of Esophagogastric Junction Outflow Obstruction\nEstima
 ted primary completion: 6 March 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07930143
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878780-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Botox (onabotulinumtoxinA): Phase 2 readout est. (NCT07878780)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2.\nStudy: MRI Study of Onab
 otulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain\nEstimated primary comp
 letion: October 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /onabotulinumtoxina#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07878780
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180394-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Botox (onabotulinumtoxinA): Phase na readout est. (NCT07180394)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase na.\nStudy: Botulinum Toxin 
 for Strabismus Treatment\nEstimated primary completion: 30 August 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/onabotulinumtoxina#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07180394
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785844-9542@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Botox (onabotulinumtoxinA): Phase 1 readout est. (NCT06785844)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 1.\nStudy: Intra-rectal Botu
 linum Toxin Injection for Intractable Non-retentive Fecal Incontinence in 
 Children - an Open Label Pilot Study\nEstimated primary completion: Septem
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/onabotulinu
 mtoxina#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06785844
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
